AZD-5069
Based on 11 publication(s) in Google Scholar
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.91%
- CAS No.: 878385-84-3
- 화학식: C18H22F2N4O5S2
- 분자량:476.52
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Small Molecule Immuno-Oncology Compound Library
HY-L031
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Chemokine Compound Library
HY-L132
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Cytokine Inhibitors Library
HY-L161
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) AZD-5069
More- Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
- J Extracell Vesicles. 2023 Jul;12(7):e12342. [Abstract]
- Cell Rep. 2023 Nov 13;42(11):113424. [Abstract]
- J Med Chem. 2024 Apr 25;67(8):6327-6343. [Abstract]
- J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]
- Cancers (Basel). 2023 Dec 1;15(23):5686. [Abstract]
- iScience. 2025 Aug 20;28(9):113407. [Abstract]
- J Med Microbiol. 2024 Apr;73(4). [Abstract]
- bioRxiv. 2024 Jul 7:2024.07.04.601620. [Abstract]
- Research Square Preprint. 2023 Dec 4.
- bioRxiv. 2023 Nov 24.
Customer Validation & Images
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Biological Activity
|
125I-IL-8-CXCR2 |
AZD-5069 (Compound 2) acts as CXCR2 antagonist by inhibition of [125I]-IL-8 binding to human CXCR2 receptors and as inhibitor of GROα-induced Ca2+ flux in human neutrophils loaded with fluo-3 dye[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 878385-84-3
-
Appearance Solid
-
분자량 476.52
-
화학식 C18H22F2N4O5S2
-
Color White to light yellow
-
SMILES
O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Pharmacological perturbation of CXCL1 signaling alleviates neuropathogenesis in a model of HEVA71 infection. [Abstract]2022 Feb 16;13(1):890. PMID: 35173169
AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.
AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
Survival rate and mean clinical score of mice infected with S41 or UI, with or without AZD5069 treatment. For AZD5069 studies, AZD5069 (10 mg/kg) or phosphate-buffered saline (PBS) was administered intracranially at 0, 2 and 4 dpi or intravenously at 0, 2, 4 and 6 dpi following UI or S41 infection in mice (sex undetermined; 25 per group) and monitored for 15 days post infection for survival rates and clinical manifestations.
AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
AZD5069 treatment lowered viral loads in brains of S41-infected mice from 4 to 7 dpi.
AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
pERK1/2 and ERK1/2 levels were reduced in AZD5069-treated mice.
AZD-5069 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Feb 16;13(1):890. [Abstract]
Brain lysates of S41- or UI-infected mice with or without AZD5069 treatment were subjected to immunoblotting analyses at 7 dpi. AZD5069 treatment delays the expression of HEVA71 viral proteins. Immunoblot representative of 3 biological repeats is shown.
-
J Extracell Vesicles
Stromal cell-derived small extracellular vesicles enhance radioresistance of prostate cancer cells via interleukin-8-induced autophagy. [Abstract]2023 Jul;12(7):e12342. PMID: 37387557 -
Cell Rep
Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. [Abstract]2023 Nov 13;42(11):113424. PMID: 37963015 -
J Med Chem
Development and Initial Characterization of the First 18F-CXCR2-Targeting Radiotracer for PET Imaging of Neutrophils. [Abstract]2024 Apr 25;67(8):6327-6343. PMID: 38570909 -
J Cereb Blood Flow Metab
2023 Sep;43(9):1503-1518. PMID: 37194247
AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]
Quantification of infarct volume and endogenous IgG positive area of mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 and vehicle 7 days after MCAO (n = 6 per group, one-way ANOVA with Bonferroni multiple comparisons test).
AZD-5069 purchased from MedChemExpress. Usage Cited in: J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518. [Abstract]
Representative MAP2 staining of brain infarct and endogenous mouse IgG staining of BBB leakage 7 days after MCAO in mice treated with AZD-5069 (10 mg/kg, icv), JNJ-47965567 or vehicle via ICV injection.
-
Cancers (Basel)
Radiation-Induced Innate Neutrophil Response in Tumor Is Mediated by the CXCLs/CXCR2 Axis. [Abstract]2023 Dec 1;15(23):5686. PMID: 38067390 -
iScience
Microenvironmental signals combine to induce non-additive molecular and phenotypic responses in mammary epithelial cells. [Abstract]2025 Aug 20;28(9):113407. PMID: 41054517 -
J Med Microbiol
2024 Apr;73(4). PMID: 38567642 -
bioRxiv
Rebalancing Viral and Immune Damage versus Tissue Repair Prevents Death from Lethal Influenza Infection. [Abstract]2024 Jul 7:2024.07.04.601620. PMID: 39372755 -
-
용액&용해도
DMSO : 90 mg/mL (188.87 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.25 mg/mL (4.72 mM); Clear solution
This protocol yields a clear solution of ≥ 2.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (22.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 12.5 mg/mL (26.23 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (276 KB)
-
SDS (643 KB)
- English - EN (643 KB)
- Français - FR (643 KB)
- Deutsch - DE (643 KB)
- Norwegian - NO (643 KB)
- Español - ES (643 KB)
- Swedish - SV (643 KB)
- Italian - IT (643 KB)
- Korean - KR (643 KB)
- Portuguese - PT (643 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0985 mL | 10.4927 mL | 20.9855 mL | 52.4637 mL |
| 5 mM | 0.4197 mL | 2.0985 mL | 4.1971 mL | 10.4927 mL | |
| 10 mM | 0.2099 mL | 1.0493 mL | 2.0985 mL | 5.2464 mL | |
| 15 mM | 0.1399 mL | 0.6995 mL | 1.3990 mL | 3.4976 mL | |
| 20 mM | 0.1049 mL | 0.5246 mL | 1.0493 mL | 2.6232 mL | |
| 25 mM | 0.0839 mL | 0.4197 mL | 0.8394 mL | 2.0985 mL | |
| 30 mM | 0.0700 mL | 0.3498 mL | 0.6995 mL | 1.7488 mL | |
| 40 mM | 0.0525 mL | 0.2623 mL | 0.5246 mL | 1.3116 mL | |
| 50 mM | 0.0420 mL | 0.2099 mL | 0.4197 mL | 1.0493 mL | |
| 60 mM | 0.0350 mL | 0.1749 mL | 0.3498 mL | 0.8744 mL | |
| 80 mM | 0.0262 mL | 0.1312 mL | 0.2623 mL | 0.6558 mL | |
| 100 mM | 0.0210 mL | 0.1049 mL | 0.2099 mL | 0.5246 mL |
AZD-5069 Related Classifications
HY-19855 Related Classifications
Powered by Bioz